T cell boosters for vaccines
Through the fusion of short fragments of the constant chain of true bone fish with antigen, the problem of cancer vaccines inducing weak T cell immune response and immune response to its own sequence in the prior art is solved, and the strong recognition and elimination of multiple antigens is achieved. , reduces the immune response to healthy tissues.
Patent Information
- Application Number
- CN201880071581.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2017-12-29
- Filing Date
- 2018-11-02
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2039-02-02
AI Technical Summary
Existing cancer vaccines are prone to tumor escape when inducing T cell immune responses, and the use of INV sequences of true bone fish closely related to humans or phylogenetic development may trigger an immune response to its own sequence, limiting the effective recognition of multiple antigens and eliminate.
Short fragments of the constant chain (INV) of true bone fish, especially 16-27 amino acid fragments of the membrane proximal domain (MPD), fused with antigens or fragments thereof, to enhance T cell responses and reduce healthy tissues. and improve the recognition ability of multiple antigens.
It effectively enhances the T cell response to multiple antigens, reduces the immune response to healthy tissues, improves the immunogenicity of cancer vaccines, and enhances the recognition and elimination of cancer-specific antigens.
Smart Images

Figure BPA0000288288260000241 
Figure BPA0000288288260000251 
Figure HPA0000288288270000011
Abstract
Description
[0001] The present invention relates to polypeptides comprising teleost constant chain fragments optionally fused to one or more antigens or teleost constant chains fused to one or more antigens or antigenic fragments thereof, polynucleotides encoding such polypeptides, vectors comprising such polynucleotides, vector collections comprising such polynucleotides, and uses of such polypeptides, polynucleotides, and vectors for treating or preventing diseases, particularly tumor diseases. Teleost constant chain polypeptides or fragments thereof are used as "T cell enhancers" for converting non-immunogenic antigen sequences into immunogenic T cell antigens. Background of the Invention
[0003] Sometimes vaccines induce suboptimal or no T cell immune responses. This phenomenon of poor induction of T cell immune responses is more often observed in the case of vaccines targeting antigens that are completely self-molecules, such as cancer-specific antigens, or partially self-antigens, such as cancer-specific neoantigens. Cancer-specific neoantigens mainly arise from point mutations in the coding regions of genes, which result in non-synonymous single nucleotide variations, which result in a change of one amino acid. Single amino acid changes in protein sequences rarely produce new epitopes that can induce effective immune responses. In most cases, such minor changes do not produce new epitopes at all, or may produce very weak new epitopes. Due to the pre-existing central tolerance to self-antigens, inducing effective immune responses against cancer-specific antigens through vaccination remains a difficult task. In order to overcome the lack or poor immunogenicity of cancer-specific antigens and neoantigens, several strategies have been adopted to rescue the lack / poor immunogenicity of some genetic vaccines. In the case of genetic vaccination, invariant chains (INVs) have been shown to enhance the induction of CD8+ T cells. Invariant chains are molecular chaperones of major histocompatibility complex (MHC) class II molecules and are required for their maturation and assembly. INV also plays a role in presenting antigenic peptides and has been shown to increase T cell induction when fused to antigen in the context of genetic vaccines. Improved immunity has been described using lentiviral vectors expressing ovalbumin fused to INV (Rowe et al. 2006 Mol Ther 13(2)310-9). Subsequently, various reports have documented the enhanced induction of CD8+ T cell responses by human adenovirus 5 and plasmid DNA vectors expressing INV fusion antigens.
[0004] In cancer vaccination, it is important to avoid tumor escape caused by the inability of vaccine-induced T cells to recognize the emergence of novel cancer-specific antigens. The challenge of cancer vaccine treatment of cancer is to induce a variety of immune T cell populations that can simultaneously recognize and eliminate as many cancer cells as possible to reduce the chance of cancer cells "escaping" T cell responses. Therefore, it is expected that the vaccine encodes a considerable number of cancer-specific antigens. This is particularly relevant to the recently described personalized vaccine approach based on cancer-specific neoantigens. In order to optimize the possibility of success, the vaccine should target as many new antigens as possible, but the maximum insert size of the vector is limited. The full-length INV sequence or its large fragments occupy a relatively large part of the vaccine antigen insert. Therefore, in the case of anti-cancer vaccination, especially when several cancer-specific antigens are used in the vaccine, it is preferred to use short polypeptides as T cell enhancers.
[0005] Genetic vaccination platforms based on adenovirus, especially ape-derived adenovirus (GAd) viral vectors, have been shown to be very effective in inducing T cell responses, and ape-derived adenovirus is suitable for encoding large antigens in the form of artificial genes consisting of polynucleotide coding segments of different proteins linked in sequence (Borthwick, N. et al., Mol Ther, 2014. 22 (2): p. 464-75). Unexpectedly, when used in the case of cancer-specific new antigens, no T cell-mediated immune response was induced.
[0006] The inventors have identified specific INV sequences that are able to restore immunogenicity, which are also referred to herein as "T cell enhancer amino acid sequences". Such T cell enhancer amino acid sequences are suitable for overcoming the lack or poor immunogenicity of cancer-specific neoantigens. In particular, two short fragments of non-human teleostei INV were identified, neither of which contained a transmembrane domain that functioned as an effective T cell enhancer.
[0007] In the case of vaccination, the use of human INV or the INV of closely related species on the phylogeny may lead to undesirable induction of immune response to the self sequence. In this case, the autoimmune response will be directed to the normal tissue expressing INV. The inventors unexpectedly found that although the INV of teleost fish is very different from the INV of mammals, the T cell response for the antigen in mammals is increased, and this T cell response enhancement is applied to the multiple antigens fused with the constant chain of teleost fish, and the teleost fish INV that is already a short fragment is enough to cause this response. Therefore, the present invention provides in particular: (i) an improved enhancer for the T cell response for the antigen in mammals, which reduces the possibility of causing harmful T cell responses for healthy tissues, (ii) an enhancer for the T cell response for multiple antigens, and (iii) a short fragment that can induce a T cell response, which maximizes the ability to fuse with a large number of antigens or their antigenic fragments. Summary of the invention
[0008] In a first aspect, the present invention provides a polypeptide comprising:
[0009] (a) a fragment of a teleost invariant chain (INV) having T cell response enhancer activity, and optionally one or more than one antigen or antigenic fragment thereof, wherein the fragment of the teleost invariant chain comprises or consists of 16 to 27 amino acids of the membrane proximal domain (MPD) of teleost INV, wherein preferably, the MPD is characterized by the following amino acid sequence:
[0010] X1QKX2QIHTLQKX3SX4RX5X6X7QX8TRX9SX 10 AV
[0011] in
[0012] X1 is G, D, S or N;
[0013] X2 is E or Q;
[0014] X3 is N or S;
[0015] X4 is D or E;
[0016] X5 is M or L;
[0017] X6 is G, N, S or T;
[0018] X7 is K or R;
[0019] X8 is L or M;
[0020] X9 is S, T or A; and
[0021] X 10 is Q or H;
[0022] wherein 16 to 27 amino acids of MPD are preferably at least 70% identical to SEQ ID NO: 7;
[0023] or
[0024] (b) a full-length teleost INV SEQ ID NO: 1 or a variant thereof having T cell response enhancer activity and one or more antigens or antigenic fragments thereof, wherein the amino acid sequence of the MPD of the variant is at least 80% identical to SEQ ID NO: 7.
[0025] In a second aspect, the present invention relates to a polynucleotide encoding a polypeptide according to the first aspect of the invention.
[0026] In a third aspect, the present invention relates to a vector comprising a polynucleotide according to the second aspect of the invention.
[0027] In a fourth aspect, the present invention relates to a collection of two or more different vectors, wherein each of the different vectors comprises a polynucleotide according to the second aspect of the invention, encoding a different polypeptide according to the first aspect of the invention.
[0028] In the fifth aspect, the present invention relates to a pharmaceutical composition comprising the polypeptide of the first aspect of the invention, the polynucleotide of the second aspect of the invention or the vector of the third aspect of the invention, or a collection of vectors of the fourth aspect of the invention, and a pharmaceutically acceptable excipient and optionally one or more adjuvants.
[0029] In a sixth aspect, the present invention relates to a kit of parts, comprising the pharmaceutical composition of the fifth aspect of the present invention, and at least one immunomodulator, such as a modulator of a checkpoint molecule (MCM), or at least one polynucleotide encoding an immunomodulator, such as MCM, or a vector comprising a polynucleotide encoding an immunomodulator, such as MCM, packaged separately.
[0030] In a seventh aspect, the present invention relates to a polypeptide according to the first aspect of the invention, a polynucleotide according to the second aspect of the invention, or a vector or a collection of vectors according to the third or fourth aspect of the invention for use as a medicament.
[0031] In an eighth aspect, the present invention relates to a polypeptide according to the first aspect of the invention, a polynucleotide according to the second aspect of the invention, or a vector or a collection of vectors according to the third or fourth aspect of the invention, or a pharmaceutical composition according to the fifth aspect of the invention or a kit comprising those pharmaceutical compositions according to the sixth aspect of the invention, for use in preventing or treating a proliferative disease, preferably cancer, a viral disease or a bacterial disease. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] Figure 1:GAd carrier at 5x10 7 vp or 5x10 8 Immunogenicity at vp dose. The vector encodes the full length of Mandarin fish INV (MF_INV_FL), the short version of Mandarin fish INV (residues 1 to 81, MF_INV_SH), Mandarin fish INV variant A (residues 62 to 88, MF_INV_A) and Mandarin fish INV variant B (residues 66 to 81, MF_INV_B) connected to the CT26 pentatope antigen. Penta means that the CT26 pentatope antigen does not have the Mandarin fish INV sequence or its fragment and has only the starting methionine. The reported values of spleen cells of immunized animals were obtained by ELISpot determination. Two weeks after vaccination, spleen cells were stimulated in vitro with five synthetic peptide libraries corresponding to the sequences of five cancer-specific new antigens containing mutations. The response is expressed as the number of T cells producing IFNγ per million spleen cells. The number of mice that showed a positive response to each vector construct tested in a total of 6 immunized mice is shown at the bottom. The dotted line represents the threshold value of the positive response.
[0033] Figure 2 : Alignment of the invariant chains of various teleost species. The first box characterizes the transmembrane domain (TMD) of 26 amino acids. The membrane proximal domain (MPD) is adjacent to the C-terminus of the TMD and is highlighted with the second box. The position and sequence of the 16 amino acid long invariant chain short fragment MF_INV_B contained in the MPD are highlighted with a series of asterisks (*) below the second box. The INV sequence is from top to bottom according to the amino acid sequence of SEQ ID NO: 3, SEQ ID NO: 6, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 1 and SEQ ID NO: 2.
[0034] Figure 3 : Immunogenicity of GAd vector encoding 20 CT26 neoantigens. 7 Mice were immunized with each GAd vector (MF_INV_A-20 containing the constant chain FRAG_A of mandarin fish, CT26-20 without the constant chain FRAG_A of mandarin fish) and the immune response was measured by ELISpot assay of spleen cells 2 weeks later. Shown are the responses (number of T cells producing IFNγ per million spleen cells) to 20 synthetic peptide pools corresponding to 20 encoded new antigen sequences. The values shown are the mean + / - SEM measured for 6 mice / group. DETAILED DESCRIPTION OF THE INVENTION
[0036] Before describing the present invention in detail below, it should be understood that the present invention is not limited to the specific methods, protocols and reagents described herein, as they may vary. It should also be understood that the terms used herein are only for the purpose of describing specific embodiments, and are not intended to limit the scope of the present invention, which is limited only by the appended claims. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art.
[0037] Preferably, the definitions of the terms used herein are as described in “A multilingual glossary of biotechnological terms: (IUPAC Recommendations)”, Leuenberger, HGW, Nagel, B. and Klb1, H. eds. (1995), Helvetica Chimica Acta, CH-4010 Basel, Switzerland), and as described in “Pharmaceutical Substances: Syntheses, Patents, Applications”, Axel Kleemann and Jurgen Engel, Thieme Medical Publishing, 1999; “Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals”, edited by Susan Budavari et al., CRC Press, 1996, and the United States Pharmacopeia-25 / National Formulary-20, published by the United States Pharmaceutical Convention, Inc., Rockville Md., 2001.
[0038] Throughout the specification and the claims that follow, unless the context requires otherwise, the words "comprise" and "comprising" will be understood to imply the inclusion of the stated features, integers or steps, or groups of features, integers or steps, but not the exclusion of any other features, integers or steps, or groups of integers or steps. In the following paragraphs, different aspects of the invention are defined in more detail. Each aspect so defined may be combined with one or more than one other aspect, unless explicitly stated to the contrary. In particular, any feature indicated as being preferred or advantageous may be combined with any other feature indicated as being preferred or advantageous.
[0039] Some documents are cited throughout this specification. Each document cited herein (including all patents, patent applications, scientific publications, manufacturer's specifications, instructions, etc.) is incorporated herein by reference in its entirety, whether above or below. Nothing herein shall be construed as an admission that the present invention is not entitled to be published in advance due to prior inventions.
[0040] definition
[0041] In the following, some definitions of terms frequently used in this specification are provided. In the remainder of the specification, these terms will have the defined meanings and preferred meanings, respectively, in each case where they are used.
[0042] The term transmembrane domain (TMD) used in the present invention refers to the TMD of the invariant chain sequence (INV), which is defined as the amino acid segment starting from the 17th residue in the N-terminal direction of the conserved Gln (Q) residue in all INVs and ending at the 8th residue in the C-terminal direction of the conserved Q, thus including a total of 26 residues.
[0043] The term membrane proximal domain (MPD) in the present invention refers to the 27 residue segment immediately C-terminal to the TMD of INV.
[0044] The term "adjuvant" is used in the present invention as a substance that enhances the immune response to an antigen. In addition, adjuvants have also been developed into substances that can help stabilize antigen preparations. Adjuvants are added to vaccines to stimulate the immune system's response to the target antigen, but they do not provide immunity by themselves. Adjuvants are needed to improve the adaptive immune response to a given route of antigen. Adjuvants work through different mechanisms. For example, by prolonging the presence of the antigen in the blood and / or helping antigen-presenting cells to absorb the antigen, and / or activating macrophages and lymphocytes, and / or supporting the production of cytokines. Some adjuvants, such as alum, are used as delivery systems that provide a slow release that continuously stimulates the immune system by creating a reservoir that captures the antigen at the injection site. Among the types of adjuvants described are: i) inorganic compounds: alum, aluminum hydroxide, aluminum phosphate, basic calcium phosphate, ii) mineral oils: paraffin oil, iii) bacterial products: inactivated Bordetella pertussis, Mycobacterium bovis, toxoids, iv) non-bacterial organic substances: squalene, v) delivery systems: detergents (Quil A), vi) plant saponins from the soap tree (see Quillaja spp.), soybean, Polygala tenuifolia, vii) cytokines: IL-1, IL-2, IL-12, viii) compositions: Freund's complete adjuvant, Freund's incomplete adjuvant.
[0045] The term "immunomodulator" in the present invention refers to any drug or substance that has an effect on the immune system. Immunomodulators can adjust the immune response to the correct level by i) strengthening a weak immune system; ii) controlling an overactive immune system. A special type of immunomodulator that can strengthen a weak immune system is a modulator of immunological checkpoint molecules (MCM), which consists of:
[0046] i) an agonistic activator MCM, such as a member of the tumor necrosis factor (TNF) receptor superfamily, preferably CD27, CD40, OX40, GITR or CD137,
[0047] ii) Antagonist inhibitors MCM, such as antagonists of PD-1, CD274, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR, LAG3, TIM-3, VISTA or B7-CD28 superfamily members, CD28 or ICOS or their ligands.
[0048] Another class of immunomodulators that can boost a weak immune system are cytokines, which act as T cell growth factors. Preferred examples of such cytokines are IL-2, IL-12, IL-15 or IL-17.
[0049] In the context of the present invention, the term "antigen" is used to refer to any structure recognized by molecules of the immune response, such as antibodies, T cell receptors (TCR), etc. Preferred antigens are cellular or exogenous, such as proteins of viruses, bacteria or fungi associated with specific diseases. Antigens are recognized by the highly variable antigen receptors (B cell receptors or T cell receptors) of the adaptive immune system and can trigger a humoral immune response or a cellular immune response. Antigens that cause such a response are also called immunogens. Whether exogenous or cellular, a portion of the intracellular proteins are processed into smaller peptides and presented by the major histocompatibility complex (MHC).
[0050] The term "antigenic fragment thereof" refers to a portion of a given antigen that is still recognized by immune system molecules. An antigenic fragment will contain at least one epitope or antigenic determinant. Preferably, an antigenic fragment of the present invention contains at least one T cell epitope.
[0051] The term "epitope", also known as antigenic determinant, is used in the context of the present invention to refer to a segment of an antigen, preferably a peptide that binds to a molecule of the immune system, such as a B cell receptor, a T cell receptor or an antibody. Epitopes that bind to antibodies or B cells are called "B cell epitopes" and epitopes that bind to T cells are called "T cell epitopes". In this context, the term "binding" preferably relates to specific binding, which is defined as the binding of an antibody or a T cell receptor (TCR) to the respective epitope in 1x10 5 M-1 or higher than 1x10 5M-1, preferably 1x10 6 M-1, 1x10 7 M-1, 1x10 8 M-1 or higher than 1x10 8 The binding constant of M-1 is combined. Technicians are well aware of how to determine the binding constant (see, for example, Caoili, SE (2012) Advances in Bioinformatics Vol. 2012). Preferably, the specific binding of the antibody to the epitope is mediated by the Fab (antigen binding fragment) region of the antibody, the specific binding of B cells is mediated by the Fab region of the antibody contained in the B cell receptor, and the specific binding of T cells is mediated by the variable (V) region of the T cell receptor. T cell epitopes are presented on the surface of antigen presenting cells and bound to major histocompatibility (MHC) molecules. There are at least two different classes of MHC molecules, namely class I MHC and class II MHC. Epitopes presented through the MHC-I pathway cause a response from cytotoxic T lymphocytes (CD8+ cells), while epitopes presented through the MHC-II pathway cause a response from T helper cells (CD4+ cells). T cell epitopes presented by class I MHC molecules are usually peptides of 8 to 11 amino acids in length, while T cell epitopes presented by class II MHC molecules are usually peptides of 13 to 17 amino acids in length. MHC class III molecules also present non-peptide epitopes in the form of glycolipids. Therefore, the term "T cell epitope" preferably refers to a peptide of 8 to 11 or 13 to 17 amino acids in length that can be presented by class I MHC or class II MHC molecules. Epitopes usually consist of chemically active surface groups of amino acids, which may or may not carry sugar side chains and usually have specific three-dimensional structural characteristics as well as specific charge characteristics. The difference between conformational epitopes and non-conformational epitopes is that in the presence of denaturing solvents, the binding to the former is lost while the binding to the latter is not lost.
[0052] In the context of the present invention, the term "cancer specific antigen" is used to refer to proteins that are specifically expressed in cancer cells or are more abundant in cancer cells than in healthy cells. Cancer specific antigens include the following types of antigens:
[0053] (i) carcinoembryonic antigen (usually expressed only in fetal tissues and cancerous somatic cells); or
[0054] (ii) oncogenic viral antigens (encoded by oncogenic viruses); or
[0055] (iii) overexpressed / accumulated antigens (expressed by both normal and neoplastic tissues, with highly elevated expression levels in tumors), such as tyrosinase in melanoma or Her-2 receptor in breast cancer; or
[0056] (iv) testicular cancer antigen (expressed only by cancer cells and adult reproductive tissues such as testis and placenta); or
[0057] (v) lineage-restricted antigens (predominantly expressed by a single cancer tissue type); or
[0058] (vi) Cancer-specific isoform antigens (alterations in transcript exon composition).
[0059] The term "cancer-specific neoantigen" as used in the context of the present invention refers to an antigen that is not present in normal cells / germ cells but is present in transformed cells, particularly cancer cells. Cancer-specific neoantigens may contain one or more than one, for example, 2, 3, 4, 5 or more than 5 new epitopes. Preferably, the length of each cancer-specific neoantigen included in the polypeptide of the present invention is selected to ensure that they are unlikely to contain epitopes present in normal cells / germ cells. Typically, this can be determined by the cancer-specific neoantigen containing 12 or fewer amino acids at the C-terminus and / or N-terminus of the amino acid changes that produce the new epitopes.
[0060] Cancer-specific neoantigens are preferably generated by mutations occurring at the DNA level, and wherein the mutated protein may comprise:
[0061] a) one or more single amino acid changes caused by a point mutation non-synonymous SNV; and / or
[0062] b) non-wild-type amino acid sequences caused by insertions / deletions that produce frameshift peptides; and / or
[0063] c) a non-wild-type amino acid sequence resulting from alterations in exon boundaries or from mutations resulting in the retention of introns; and / or
[0064] d) Mutated oncoproteins resulting from gene fusion events.
[0065] Neoantigens generated by one or more than one single amino acid changes caused by genomic point mutation non-synonymous SNVs are referred to as single amino acid mutant peptides in the context of the present invention.
[0066] The term "frameshift peptide" as used in the context of the present invention refers to the complete non-wild-type translation product of a protein-coding segment of a polynucleotide comprising an insertion or deletion mutation causing an open reading frame (ORF) shift.
[0067] In the context of the present invention, the term "open reading frame" is abbreviated as "ORF" and refers to a nucleotide sequence that can be translated into a continuous amino acid sequence. Typically, in a given reading frame, an ORF includes a start codon, a subsequent region that is usually a multiple of 3 nucleotides in length, but does not include a stop codon (TAG, TAA, TGA, UAG, UAA or UGA). In the protein encoded by the ORF, the amino acids that can be translated form a chain of peptide connections.
[0068] The term "polynucleotide" or "nucleic acid" includes single-stranded and double-stranded nucleotide polymers. The nucleotides comprising the polynucleotide can be ribonucleotides or deoxyribonucleotides or modified forms of either type of nucleotide. The modifications include base modifications, such as bromouridine and inosine derivatives, ribose modifications, such as 2', 3'-dideoxyribose, and internucleotide linkage modifications, such as phosphorothioate, phosphorodithioate, phosphoselenate, phosphodiselenate, anilinothioate (phosphoroanilothioate), anilinophosphate (phoshoraniladate) and phosphoramidate. Examples of polynucleotides are DNA and RNA.
[0069] An "isolated polynucleotide" is a DNA or RNA of genomic, mRNA, cDNA, or synthetic origin, or some combination thereof, that is independent of, or linked to, polynucleotides to which all or part of a polynucleotide is not naturally linked as found in nature.
[0070] In the context of the present invention, the term "expression cassette" is used to refer to a polynucleotide comprising at least one nucleic acid sequence to be expressed, the nucleic acid sequence to be expressed being, for example, a sequence encoding a cancer-specific neoantigen or a fragment thereof fused to the invariant chain of the present invention, the expression cassette being operably linked to a transcription and / or translation control sequence. Preferably, the expression cassette includes cis-regulatory elements, such as promoters, start sites and / or polyadenylation sites, for effectively expressing a given gene. Preferably, the expression cassette includes all other elements required for expressing the polynucleotide in the patient's cells. Thus, a typical expression cassette includes a promoter operably linked to the polynucleotide sequence to be expressed, and signals required for effective polyadenylation, ribosome binding sites and translation termination of the transcript. Other elements of the cassette may include, for example, enhancers. The expression cassette preferably also includes a transcription termination region located downstream of the structural gene to provide effective termination. The termination region may be obtained from the same gene as the promoter sequence, or may be obtained from a different gene.
[0071] The term "operably linked" as used in the context of the present invention refers to an arrangement of elements in which the components so described are configured to perform their usual functions. A polynucleotide is "operably linked" when it is in a functional relationship with another nucleic acid sequence. For example, if a promoter affects the transcription of one or more transgenes, the promoter is operably linked to one or more transgenes. In addition, control elements operably linked to a coding sequence are able to achieve expression of the coding sequence. Control elements do not have to be adjacent to the coding sequence, as long as they have the function of directing its expression. Thus, for example, there can be an intervening untranslated but still transcribed sequence between the promoter sequence and the coding sequence, and the promoter sequence can still be considered to be "operably linked" to the coding sequence.
[0072] The terms "vector" or "expression vector" are used interchangeably and refer to a polynucleotide, a polynucleotide within a certain type of envelope, such as a viral capsid or liposome, or a polynucleotide complexed with a protein that can be introduced into or can introduce a polynucleotide of the present invention or introduce a polynucleotide of the present invention into a cell, preferably a mammalian cell. Examples of vectors include, but are not limited to, plasmids, cosmids, bacteriophages, liposomes, viruses, or artificial chromosomes. In particular, a vector is used to transport the promoter and polynucleotide of the present invention into a suitable host cell. The expression vector may contain a "replicon" polynucleotide sequence that promotes autonomous replication of the expression vector in the host cell. After entering the host cell, the expression vector can replicate independently of the host chromosomal DNA or simultaneously with the host chromosomal DNA, and multiple copies of the vector and its inserted DNA can be generated. If an expression vector with poor replication function is used (usually for safety reasons), the vector may not replicate and can only directly express the polynucleotide. Depending on the type of expression vector, the expression vector may not be lost from the cell, i.e., only transiently express the new antigen encoded by the polynucleotide, or may be stable in the cell. The expression vector generally contains an expression cassette, i.e., an essential element that allows the polynucleotide to be transcribed into an mRNA molecule. If the polynucleotide is RNA, transcription is not required and the RNA molecule requires only translational control elements.
[0073] The term "T cell enhancer amino acid sequence" refers to a polypeptide sequence that, when fused to an antigen sequence, increases T cell induction in the context of genetic vaccination.
[0074] The term "T cell response enhancer activity" refers to a compound, particularly a polypeptide, that increases the response of T cells attacked by an antigen. Examples of such compounds are polypeptides of the present invention, particularly when coupled to an antigen sequence. In the case of vaccination, the polypeptide will increase the response of T cells to the antigen compared to the response of T cells to the antigen alone. Suitable assays for measuring T cell responses are known in the art, including measuring cytokines released by activated T cells by ELISpot or by intracellular cytokine staining (ICS), such as interferon gamma (IFN-γ), which detects the production and accumulation of cytokines in the endoplasmic reticulum after cell stimulation. Compounds with T cell response enhancing activity, as exemplified, increase the response of T cells, for example, by increasing cytokine release.
[0075] The terms "formulation" and "composition" as used in the context of the present invention are intended to include formulations of active compounds, such as simian adenoviruses of the present invention, with carriers and / or excipients.
[0076] As used in the context of this invention, "pharmaceutically acceptable" refers to drugs approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
[0077] As used herein, the term "carrier" refers to a pharmacologically inactive substance, such as, but not limited to, a diluent, excipient, surfactant, stabilizer, physiological buffer solution or carrier administered with a therapeutically active ingredient. Such a pharmaceutical carrier can be liquid or solid. Liquid carriers include, but are not limited to, sterile liquids, such as saline solutions in water and oils, including, but not limited to, those of petroleum, animal, plant or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, etc. Saline solutions as well as aqueous glucose and glycerol solutions can also be used as liquid carriers, particularly for injectable solutions. When the pharmaceutical composition is administered intravenously, saline solutions are preferred carriers. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by EWMartin.
[0078] Suitable pharmaceutical "excipients" include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glyceryl monostearate, talc, sodium chloride, skimmed milk powder, glycerol, propylene, ethylene glycol, water, ethanol and the like.
[0079] “Surfactants” include anionic surfactants, cationic surfactants, and nonionic surfactants, such as, but not limited to, sodium deoxycholate, sodium dodecyl sulfate, Triton X-100, and polysorbates, such as polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 65, and polysorbate 80.
[0080] "Stabilizers" include, but are not limited to, mannitol, sucrose, trehalose, albumin, and protease and / or nuclease antagonists.
[0081] "Physiological buffer solutions" that can be used in the context of the present invention include, but are not limited to, sodium chloride solutions, deionized water, and suitable organic or inorganic buffer solutions, such as, but not limited to, phosphate buffers, citrate buffers, tris buffers (tris(hydroxymethyl)aminomethane), HEPES buffers ([4(2-hydroxyethyl)piperazine]ethanesulfonic acid) or MOPS buffers (3-morpholino-1-propanesulfonic acid). Typically, the selection of each buffer depends on the desired buffer molar concentration. Phosphate buffers are suitable for, for example, injections and infusions.
[0082] An "effective amount" or "therapeutically effective amount" is an amount of a therapeutic agent sufficient to achieve its intended purpose. The effective amount of a given therapeutic agent will vary with factors such as the nature of the therapeutic agent, the route of administration, the size and type of animal receiving the therapeutic agent, and the purpose of administration. The effective amount in each case can be determined empirically by a skilled artisan according to methods established in the art.
[0083] As used herein, "treatment" or "treating" of a disease or condition means accomplishing one or more of the following: (a) reducing the severity of the disease; (b) limiting or preventing the development of symptoms characteristic of the treated condition; (c) inhibiting the worsening of symptoms characteristic of the treated condition; (d) limiting or preventing the recurrence of the condition in an individual who previously had the condition; and (e) limiting or preventing the recurrence of symptoms in an individual who previously had symptoms of the condition.
[0084] Embodiments of the invention
[0085] In a first aspect, the present invention provides a polypeptide comprising:
[0086] (a) preferably a fragment of teleost INV having T cell response enhancer activity and optionally one or more than one antigen or antigenic fragment thereof, wherein the fragment of teleost INV comprises or consists of 16 to 27 consecutive amino acids of the membrane proximal domain (MPD) of teleost INV, wherein preferably, MPD is characterized by the following amino acid sequence (SEQ ID NO: 31):
[0087] X1QKX2QIHTLQKX3SX4RX5X6X7QX8TRX9SX 10 AV
[0088] in
[0089] X1 is G, D, S or N, preferably G or S; more preferably G;
[0090] X2 is E or Q; preferably E;
[0091] X3 is N or S; preferably N;
[0092] X4 is D or E; preferably E;
[0093] X5 is M or L; preferably M;
[0094] X6 is G, N, S or T; preferably S, G or T, more preferably S;
[0095] X7 is K or R; preferably K;
[0096] X8 is L or M; preferably L;
[0097] X9 is S, T or A; preferably S; and
[0098] X 10 is Q or H; preferably Q;
[0099] wherein 16 to 27 amino acids of MPD are preferably at least 70% identical to SEQ ID NO: 7;
[0100] or
[0101] (b) a full-length teleost INV SEQ ID NO: 1 or a variant thereof having T cell response enhancer activity and one or more antigens or antigenic fragments thereof, wherein the amino acid sequence of the MPD of the variant is at least 80% identical to SEQ ID NO: 7.
[0102] Generally, it is desirable that the fragment of INV is as short as possible while retaining its T cell antigen stimulatory effect. Preferably, the fragment comprises, more preferably consists of, 16 to 27, 17 to 26, 18 to 25, 19 to 24, 20 to 23, 21 to 22 consecutive amino acids of the MPD of INV.
[0103] Although fragments of INV may contain additional sequences at the N-terminus and / or C-terminus of MPD, preferably, the fragment does not contain such sequences, and thus, preferably, the fragment consists of the corresponding continuous amino acid stretch of MPD.
[0104] If the fragment of INV contains additional sequences at the N-terminus and / or C-terminus of MPD, then preferably the fragment contains the entire MPD, i.e. 27 amino acids. Preferably, the fragment does not contain TMD, but contains the other C-terminal amino acids of INV. Preferably, these C-terminal amino acids are directly and continuously connected to MPD.
[0105] The sequence of MPD is preferably based on the MPD sequence of mandarin fish according to SEQ ID NO: 7. Preferably, the fragment comprises or consists of 16 to 27 amino acids of MPD, wherein MPD is at least 75%, more preferably at least 80%, more preferably at least 85%, more preferably at least 90%, more preferably at least 95% identical to SEQ ID NO: 7.
[0106] The fragment may comprise the N-terminal and / or C-terminal amino acid sequence of another INV. Therefore, the total length of the preferred INV fragment is 16 to 80, 17 to 72, 18 to 55, 19 to 50, 20 to 45, 21 to 40, 22 to 35, 23 to 30 continuous amino acids.
[0107] In a preferred embodiment, the fragment comprises or consists of an MPD characterized by the amino acid sequence of SEQ ID NO: 31. Preferably, the MPD comprises at least the amino acid sequence of QIHTLQKX3SX4RX5X6X7QX8 (SEQ ID NO: 51), wherein
[0108] X3 is N or S; preferably N;
[0109] X4 is D or E; preferably E;
[0110] X5 is M or L; preferably M;
[0111] X6 is G, N, S or T; preferably S, G or T, more preferably S;
[0112] X7 is K or R; preferably K;
[0113] X8 is L or M; preferably L.
[0114] In the context of this preferred embodiment, it is particularly preferred that the fragment comprises SEQ ID NO: 51 and 0 to 11, i.e. 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 further amino acids of MPD which may be located at the N-terminus and / or C-terminus of SEQ ID NO: 51. Preferably, these 1 to 11 further amino acids have at least 70% identity with SEQ ID NO: 7. Preferably, the entire fragment comprising the core sequence according to SEQ ID NO: 51 is at least 70% identical to SEQ ID NO: 7, more preferably at least 75% identical to SEQ ID NO: 7, more preferably at least 80% identical, even more preferably at least 85% identical, or at least 90% identical. In each case, it is preferred that the fragment has T cell response enhancer activity. It is also preferred that no further INV chain sequences are continuously linked to the N-terminus and C-terminus of the fragment, and more preferably the fragment is the only INV sequence in the polypeptide.
[0115] In a preferred embodiment of the polypeptide of the first aspect of the invention:
[0116] (a) The amino acid sequence of the MPD of alternative (a) of the first aspect is any one of SEQ ID NOs: 7 to 12, i.e. SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12; or
[0117] (b) The amino acid sequence of the INV fragment of alternative (a) of the first aspect of the invention comprises any one of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17 or SEQ ID NO: 18, preferably comprises SEQ ID NO: 7 or SEQ ID NO: 13; or consists of any one of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17 or SEQ ID NO: 18, preferably consists of SEQ ID NO: 7 or SEQ ID NO: 13; or
[0118] (c) The amino acid sequence of the teleost invariant chain of alternative (b) of the first aspect of the present invention is any one of SEQ ID NOs: 1 to 6.
[0119] If the fragment consists of 16 to 27 amino acids of the MPD of INV, preferred fragments have a length of 16 to 27, 17 to 26, 18 to 25, 19 to 24, 20 to 23, 21 to 22 consecutive amino acids according to the MPD of INV of SEQ ID NOs: 7 to 12.
[0120] In each case outlined above, the fragment or variant has T cell response enhancer activity. T cell response enhancer activity can be measured as known in the art or as described in the accompanying experiments. When linked to the same antigen or antigen fragment, preferably the T cell response enhancer activity is at least 50%, preferably at least 80% of the T cell response enhancer activity of the INV fragment according to SEQ ID NO: 13.
[0121] In a particular embodiment of the polypeptide of alternative (a) of the first aspect of the invention, the fragment consists of at least the 16 to 27 N-terminal amino acids of MPD and:
[0122] (i) 1 to 26 consecutive amino acids of the transmembrane domain (TMD) of a teleost fish INV immediately N-terminal to the MPD, wherein the TMD of the teleost fish INV is preferably characterized by the following amino acid sequence (SEQ ID NO: 32):
[0123] AY1KY2AY3LTTLY4CLLY5Y6SQVFTAYY7VF
[0124] in
[0125] Y1 is L or F, preferably L;
[0126] Y2 is I or V, preferably V;
[0127] Y3 is G or A, preferably G;
[0128] Y4 is T or A, preferably T;
[0129] Y5 is L or V, preferably L;
[0130] Y6 is A or S, preferably A; and
[0131] Y7 is M or T, preferably M;
[0132] and / or
[0133] (ii) 1 to 19 consecutive amino acids of a teleost INV immediately following the C-terminus of MPD, preferably characterized by the following amino acid sequence (SEQ ID NO: 33):
[0134] APZ1Z2MZ3Z4PMZ5SLPZ6Z7Z8DZ9Z 10
[0135] in
[0136] Z1 is M, V or A, preferably M or V, more preferably M;
[0137] Z2 is R or K, preferably K;
[0138] Z3 is H, A or Q, preferably M or H, more preferably H;
[0139] Z4 is M or L, preferably M;
[0140] Z5 is N or S, preferably N;
[0141] Z6 is M or L, preferably L;
[0142] Z7 is M, L or V, preferably L;
[0143] Z8 is M or S, preferably M;
[0144] Z9 is F or Y, preferably F; and
[0145] Z 10 It is T or S, preferably T.
[0146] If the fragment comprises the N-terminal and / or C-terminal amino acid sequence of another INV, it is preferred that the full length of the fragment of INV is 28 to 72, 30 to 65, or 35 to 46 consecutive amino acids.
[0147] The inventors unexpectedly found that by fusing the INV fragments of the alternative (a) of the first aspect of the present invention or the INV of the alternative (b) of the first aspect of the present invention with two or more antigens and / or its antigen fragment, it is possible to induce a strong T cell response to two or more antigens, preferably a new antigen. This allows for simultaneous induction of T cell responses for multiple antigens. Therefore, with respect to the alternative (a) of the first aspect of the present invention and the alternative (b) of the first aspect of the present invention, it is preferred that the polypeptide comprises multiple antigens and / or its antigen fragment. For example, it is preferred that the polypeptide comprises at least 5 different antigens and / or its antigen fragment, more preferably at least 20 different antigens and / or its antigen fragment, even more preferably at least 50 different antigens and / or its antigen fragment, even more preferably at least 100 different antigens and / or its antigen fragment, even more preferably at least 200 different antigens and / or its antigen fragment, even more preferably at least 300 different antigens and / or its antigen fragment.
[0148] In order to accommodate the maximum number of different antigens in one polypeptide, it is particularly preferred that the polypeptide comprises antigenic fragments of antigens.
[0149] The antigen is selected according to the corresponding therapeutic application. If treatment or vaccination is required for a proliferative disease, the antigen is selected from a cancer-specific antigen or a cancer-specific neoantigen. As described above, in particular in the context of cancer vaccination, it is preferred that the polypeptide of the first aspect comprises two or more different antigens. Preferably, the polypeptide comprises at least 5 different cancer-specific antigens or antigenic fragments thereof, more preferably at least 20 different cancer-specific antigens or antigenic fragments thereof, even more preferably at least 50 different cancer-specific antigens or antigenic fragments thereof, even more preferably at least 100 different cancer-specific antigens or antigenic fragments thereof, even more preferably at least 200 different cancer-specific antigens or antigenic fragments thereof, even more preferably at least 300 different cancer-specific antigens or antigenic fragments thereof. Alternatively, preferably the polypeptide comprises at least 5 different cancer-specific neoantigens or antigenic fragments thereof, more preferably at least 20 different cancer-specific neoantigens or antigenic fragments thereof, even more preferably at least 50 different cancer-specific neoantigens or antigenic fragments thereof, even more preferably at least 100 different cancer-specific neoantigens or antigenic fragments thereof, even more preferably at least 200 different cancer-specific neoantigens or antigenic fragments thereof, even more preferably at least 300 different cancer-specific neoantigens or antigenic fragments thereof. Alternatively, preferably the polypeptide comprises at least 5 different cancer-specific antigens or neoantigens or antigenic fragments thereof, more preferably at least 20 different cancer-specific antigens or neoantigens or antigenic fragments thereof, even more preferably at least 50 different cancer-specific antigens or neoantigens or antigenic fragments thereof, even more preferably at least 100 different cancer-specific antigens or neoantigens or antigenic fragments thereof, even more preferably at least 200 different cancer-specific antigens or neoantigens or antigenic fragments thereof, even more preferably at least 300 different cancer-specific antigens or neoantigens or antigenic fragments thereof.
[0150] Alternatively, the antigen is a viral protein or antigenic fragment thereof, a bacterial protein or antigenic fragment thereof, or a fungal protein or antigenic fragment thereof.
[0151] Generally, preventive or therapeutic vaccines for viral, bacterial or fungal infections do not require multiple different effective antigens like the vaccine for the treatment of proliferative diseases. Nevertheless, some viruses, such as HIV, have a large number of different epitopes, particularly in the coating protein. In order to cause a wide range of immune responses, multiple antigens can be included. Therefore, preferably the polypeptide comprises at least 5 different viral antigens or their antigenic fragments, more preferably at least 20 different viral antigens or their antigenic fragments, even more preferably at least 50 different viral antigens or their antigenic fragments, even more preferably at least 100 different viral antigens or their antigenic fragments, even more preferably at least 200 different viral antigens or their antigenic fragments, even more preferably at least 300 different viral antigens or their antigenic fragments. Antigen can be selected from different viral strains of the same virus and / or selected from different viruses. In the latter case, the vaccine can produce immunity for multiple different viruses.
[0152] Alternatively, preferably the polypeptide comprises at least 5 different bacterial antigens or antigenic fragments thereof, more preferably at least 20 different bacterial antigens or antigenic fragments thereof, even more preferably at least 50 different bacterial antigens or antigenic fragments thereof, even more preferably at least 100 different bacterial antigens or antigenic fragments thereof, even more preferably at least 200 different bacterial antigens or antigenic fragments thereof, even more preferably at least 300 different bacterial antigens or antigenic fragments thereof.
[0153] Alternatively, preferably the polypeptide comprises at least 5 different fungal antigens or antigenic fragments thereof, more preferably at least 20 different fungal antigens or antigenic fragments thereof, even more preferably at least 50 different fungal antigens or antigenic fragments thereof, even more preferably at least 100 different fungal antigens or antigenic fragments thereof, even more preferably at least 200 different fungal antigens or antigenic fragments thereof, even more preferably at least 300 different fungal antigens or antigenic fragments thereof.
[0154] In all of the above embodiments, preferably the antigen is a T cell antigen. T cell antigens are those that are presented by MHC and elicit a T cell response.
[0155] Preferably, the or each antigen or antigenic fragment thereof is from 6 to 100 amino acids in length, more preferably from 7 to 50 amino acids, more preferably from 8 to 30 amino acids in length.
[0156] In a preferred embodiment of the polypeptide of the first aspect of the invention, one or more than one antigen and / or one or more than one antigen fragment thereof is located at the C-terminus of the INV fragment according to alternative (a) of the first aspect of the invention or at the C-terminus of the full-length INV according to alternative (b) of the first aspect of the invention. It is particularly preferred that the antigen and / or its antigen fragment is immediately at the C-terminus of the INV according to alternative (a) or (b) of the first aspect of the invention.
[0157] Preferably, the polypeptide of the present invention is produced in the cells of the patient to be vaccinated. Intracellular expression is a prerequisite for MHC presentation and thus stimulation of T cell responses. Therefore, in a second aspect, the present invention relates to a polynucleotide encoding a polypeptide according to the first aspect of the present invention. Preferably, the polynucleotide is DNA or RNA. More preferably, the polynucleotide is DNA. RNA is preferably used to directly trigger the translation of the encoded polypeptide. The DNA encoding the first aspect polypeptide is usually inserted into an expression cassette that directs the transcription of the mRNA encoding the polypeptide of the present invention. However, if the polynucleotide is contained in a vector and the vector is an RNA virus, the polynucleotide may also be RNA. The preferred RNA for direct application is self-amplifying RNA (SAM).
[0158] In a third aspect, the present invention relates to a vector comprising a polynucleotide according to the second aspect of the invention. Preferably, the polynucleotide of the invention is operably linked to an expression control sequence.
[0159] If the number of different antigens or antigenic fragments thereof to be delivered to the patient is so large that the polynucleotide encoding the fusion polypeptide of INV and all antigens or antigenic fragments thereof cannot be accommodated in the selected vector, two or more vectors are used. Therefore, in a fourth aspect, the present invention relates to a collection of two or more different vectors, wherein each of the different vectors comprises a polynucleotide encoding a different polypeptide according to the first aspect of the present invention according to the second aspect of the present invention.
[0160] For the vector of the third aspect or the vector set of the fourth aspect, the vector is independently selected from plasmids, cosmids, liposome particles, viral vectors or virus-like particles in each case; preferably alphavirus vectors, Venezuelan equine encephalitis (VEE) virus vectors, Sindbis (SIN) virus vectors, forest encephalitis virus (SFV) virus vectors, simian or human cytomegalovirus (CMV) vectors, lymphocytic choriomeningitis virus (LCMV) vectors, retrovirus vectors, lentivirus vectors, adenovirus vectors, adeno-associated virus vectors, poxvirus vectors, vaccinia virus vectors or modified vaccinia Ankara (MVA) vectors. Preferred is a collection of vectors, wherein each member of the collection comprises a polynucleotide encoding a different antigen or fragment thereof, so that the vectors usually administered simultaneously use the same vector type, such as adenovirus-derived vectors.
[0161] The most preferred vector is an adenoviral vector, particularly an adenoviral vector derived from a human or non-human ape. Preferred apes from which adenoviruses are derived are chimpanzees (Pan), gorillas (Gorilla) and orangutans (Pongo), preferably bonobos (Pan paniscus) and chimpanzees (Pan troglodytes). Typically, naturally occurring non-human ape adenoviruses are isolated from fecal samples of the corresponding apes. The most preferred vectors are replication-incompetent adenovirus vectors based on hAd5, hAd11, hAd26, hAd35, hAd49, ChAd3, ChAd4, ChAd5, ChAd6, ChAd7, ChAd8, ChAd9, ChAd10, ChAd11, ChAd16, ChAd17, ChAd19, ChAd20, ChAd22, ChAd24, ChAd26, ChAd30, ChAd31, ChAd37, ChAd38, ChAd44, ChAd55, ChAd63, ChAd73, ChAd82, ChAd83, ChAd146, ChAd147, PanAd1, PanAd2 and PanAd3 vectors, or replication-competent Ad4 and Ad7 vectors. Human adenovirus hAd4, hAd5, hAd7, hAd11, hAd26, hAd35 and hAd49 are well known in the art. Vectors based on naturally occurring ChAd3, ChAd4, ChAd5, ChAd6, ChAd7, ChAd8, ChAd9, ChAd10, ChAd11, ChAd16, ChAd17, ChAd19, ChAd20, ChAd22, ChAd24, ChAd26, ChAd30, ChAd31, ChAd37, ChAd38, ChAd44, ChAd63, and ChAd82 are described in detail in WO 2005 / 071093. Vectors based on naturally occurring PanAd1, PanAd2, PanAd3, ChAd55, ChAd73, ChAd83, ChAd146, and ChAd147 are described in detail in WO 2010 / 086189.
[0162] In the fifth aspect, the present invention relates to a pharmaceutical composition comprising a polypeptide of the first aspect of the invention, a polynucleotide of the second aspect of the invention or a vector of the third aspect of the invention, or a collection of vectors of the fourth aspect of the invention, and a pharmaceutically acceptable excipient and optionally one or more adjuvants.
[0163] The inventors found that at least one immunomodulator, such as a regulator of a checkpoint molecule (MCM), further improved the intensity of T cell responses to an antigen or a fragment thereof. Therefore, in a preferred embodiment of the sixth aspect, the pharmaceutical composition comprises at least one immunomodulator such as MCM, or at least one polynucleotide encoding the immunomodulator such as MCM, or a vector or liposome particles comprising a polynucleotide encoding the immunomodulator such as MCM.
[0164] In a sixth aspect, the present invention relates to a kit of parts, comprising the pharmaceutical composition of the fifth aspect of the present invention, and at least one immunomodulator such as MCM, or at least one polynucleotide encoding an immunomodulator such as MCM, or a vector comprising a polynucleotide encoding an immunomodulator such as MCM, which are packaged separately.
[0165] In a preferred embodiment of the fifth aspect or the sixth aspect, the immunomodulator is an MCM and is selected from:
[0166] (a) an agonist of a member of the tumor necrosis factor (TNF) receptor superfamily, preferably an agonist of CD27 (e.g., Varlilumab), CD40 (e.g., CP-870, 893), OX40 (e.g., INCAGN01949 or MEDI0562), GITR (e.g., MEDI1873), or CD137 (e.g., Urotomimab);
[0167] (b) antagonists of PD-1 (e.g., pembrolizumab or nivolumab), antagonists of CD274 (atezolizumab or durvalumab), antagonists of A2AR (e.g., Preladenant), antagonists of B7-H3 (e.g., MGA271), antagonists of B7-H4, antagonists of BTLA, antagonists of CTLA-4 (e.g., tremelimumab or AGEN1884), antagonists of IDO, antagonists of KIR, antagonists of LAG3, antagonists of TIM-3 (e.g., CA-327 or RMT3-23), or antagonists of VISTA (e.g., CA-170), or antagonists of members of the B7-CD28 superfamily, preferably antagonists of CD28 or ICOS or antagonists of their ligands.
[0168] Other preferred immunomodulators are cytokines which act as T-cell growth factors, in particular IL-2, IL-12 or IL-15.
[0169] In a seventh aspect, the present invention relates to a polypeptide according to the first aspect of the invention, a polynucleotide according to the second aspect of the invention, or a vector or a collection of vectors according to the third or fourth aspect of the invention for use as a medicament.
[0170] In an eighth aspect, the present invention relates to a polypeptide according to the first aspect of the invention, a polynucleotide according to the second aspect of the invention, or a vector or a collection of vectors according to the third or fourth aspect of the invention, or a pharmaceutical composition according to the fifth aspect of the invention or a kit comprising those pharmaceutical compositions according to the sixth aspect of the invention, for use in preventing or treating a proliferative disease, preferably cancer, a viral disease, a fungal disease or a bacterial disease.
[0171] In a preferred embodiment, the polypeptide according to the first aspect of the invention, the polynucleotide according to the second aspect of the invention, or the vector or a collection of vectors according to the third or fourth aspect of the invention, or the pharmaceutical composition according to the fifth aspect of the invention, or a kit comprising such a pharmaceutical composition according to the fifth aspect of the invention, wherein the cancer is selected from: malignant tumors of the lips, oral cavity, pharynx, digestive organs, respiratory organs, thoracic organs, bones, articular cartilage, skin, mesothelial tissue, soft tissue, breast, female reproductive organs, male reproductive organs, urinary tract, brain and other parts of the central nervous system, thyroid, endocrine glands, lymphatic tissue and hematopoietic tissue.
[0172] In a preferred embodiment, the polypeptide according to the first aspect of the present invention, the polynucleotide according to the second aspect of the present invention, or the vector or a collection of vectors according to the third or fourth aspect of the present invention, or the pharmaceutical composition according to the fifth aspect of the present invention, or a kit comprising such a pharmaceutical composition according to the fifth aspect of the present invention, wherein before, simultaneously with or after the administration of the polypeptide according to the first aspect of the present invention, the polynucleotide according to the second aspect of the present invention, or the vector or a collection of vectors according to the third or fourth aspect of the present invention, or the pharmaceutical composition according to the fifth aspect of the present invention, or a kit comprising such a pharmaceutical composition according to the fifth aspect of the present invention, at least one immunomodulator, such as MCM, or at least one polynucleotide encoding the immunomodulator, such as MCM, or a vector or liposome particle comprising a polynucleotide encoding the immunomodulator, such as MCM is administered.
[0173] In a preferred embodiment of the eighth aspect of the invention, administration of the modulator of the checkpoint molecule is initiated before administration of the vaccine is initiated, or wherein administration of the checkpoint inhibitor is initiated after administration of the vaccine is initiated, or wherein administration of the checkpoint inhibitor is initiated simultaneously with initiation of vaccination.
[0174] In a preferred embodiment of the eighth aspect of the invention, the vaccination regimen is a heterologous prime boost immunization using two different viral vectors. The preferred combination is a simian-derived adenovirus vector for priming and a poxvirus vector, a vaccinia virus vector or a modified vaccinia Ankara (MVA) vector for boosting. Preferably, these vectors are administered sequentially at an interval of at least 1 week, preferably 6 weeks. Example
[0175] Example 1: Fusion of a neoantigen with a Siniperca chuatsi invariant chain or fragment thereof produces immunogenicity in the context of simian adenovirus vaccination
[0176] The selected cancer-specific neoantigens were generated by 5 non-synonymous single nucleotide variants (SNVs), which are the most common mutation types found in tumors. The amino acid sequence of each cancer-specific neoantigen has the mutated amino acid located at its center, flanked by 12 wild-type (wt) amino acids upstream and downstream, with a total length of 25 amino acids (Table 1). The neoantigen sequences were connected end to end to form an artificial antigen.
[0177] A simian adenovirus vector (GAd) encoding a pentatope (Penta: SEQ ID NO: 25) containing five cancer-specific neoantigens (Table 1) preceded by a methionine initiator derived from a CT26 murine tumor failed to induce an immune response against the cancer-specific neoantigens ( Figure 1 ), except that the Siniperca chuatsi invariant chain (INV) sequence (MF_INV_FL: SEQ ID NO: 26), or a truncated version of Siniperca chuatsi INV including residues 1 to 81 including the transmembrane domain (MF_INV_SH, SEQ ID NO: 27), or a fragment of the Siniperca chuatsi INV sequence preceded by a methionine initiator (MF_INV_A: SEQ ID NO: 28; MF_INV_B: SEQ ID NO: 29) was placed at the N-terminus of the pentatope. In all constructs, the HA peptide sequence (SEQ ID NO: 30) for monitoring expression was fused downstream of the pentatope.
[0178] For each vaccine construct, 5x10 8 or 5x10 7 The immunity of BalBC inbred mice was evaluated after a single intramuscular immunization with a dose of 100 GAd virus particles (vp). Splenocytes were collected three weeks after immunization and tested by IFN-γ ELISpot by stimulating the cells in the presence of a 25-mer synthetic peptide pool corresponding to each of the five cancer-specific neoantigens. IFN-γ ELISpot assays were performed on single-cell suspensions of spleen. MSIP S4510 plates (Millipore, Billerica, MA) were coated with 10 μg / ml anti-mouse IFN-γ antibody (U-CyTech Utrecht, The Netherlands) and incubated overnight at 4°C. After washing and blocking, mouse splenocytes were plated at two different densities (1×10 per well). 6 and 5×10 5Cells were plated in duplicate and stimulated overnight with a peptide pool containing five 25-mer peptides at a final concentration of 1 μg / ml. Peptide diluent dimethyl sulfoxide (Sigma-Aldrich, Milan, Italy) was used as a negative control. The cells were then incubated with biotinylated anti-mouse IFN-γ antibody (U-CyTech Utrecht, The Netherlands), conjugated streptavidin-alkaline phosphatase (BD Biosciences, San Jose, CA), and finally with 5-bromo-4-chloro-3-indolyl phosphate / nitro blue tetrazolium. The plates were developed by incubation with 1-step solution (Thermo Fisher Scientific, Rockford, IL). The plates were analyzed using an automated ELISA-spot technology video analysis system automated plate reader. ELISpot data are expressed as IFN-γ SFC per million splenocytes.
[0179] Immune response (number of T cells producing IFN-γ per million splenocytes) Figure 1 If (i) the average of the antigen wells is greater than 20 spots forming colony SFC / 10 6 PBMC, and (ii) greater than 3 times the background value of wells incubated with the peptide diluent DMSO, the response was considered positive. Figure 1 As shown, in 5x10 8 vp, the addition of Siniperca chuatsi INV or its fragments to animals vaccinated with MF_INV_FL or MF_INV_A converted the non-immunogenic Penta antigen into an immunogenic antigen with a 100% response rate. In particular, constructs containing the short fragments MF_INV_A or MF_INV_B were used at 5x10 8 The immunogenicity induced by vaccination with 5x10 vp was comparable to that observed with either the full-length Siniperca chuatsi INV (MF_INV_FL) or a truncated version of Siniperca chuatsi INV (MF_INV_SH) comprising residues 1 to 81 including the transmembrane domain. 7 Vaccination of vp Figure 1 ) could distinguish the potency of different T cell enhancers, among which the construct containing the short fragment MF_INV_A was the only one able to rescue immunogenicity in 100% of mice, at a level comparable to that observed in the construct containing the full-length Siniperca chuatsi INV (MF_INV_FL).
[0180] A truncated version of Mandarin fish INV (MF_INV_SH), comprising residues 1 to 81 including the transmembrane domain, was instead inferior to MF_INV_A and could only induce an immune response in 1 out of 6 mice at a lower dose.
[0181] Table 1
[0182] Penta antigen: Composition of penta antigen. CT26 neoantigens are present in the assembled penta antigen in the order shown. The mutated amino acids of each neoantigen are shown in bold and underlined.
[0183]
[0184] Embodiment 2:
[0185] The ability of the mandarin fish constant chain fragment MF_INV_A (SEQ ID NO: 7) to enhance vaccine-induced immune responses was then further tested using a novel artificial antigen containing a large number (20) of neoantigens from the CT26 mouse model. All five neoantigens present in the construct MF_INV_A from Example 1 (Table 1) were included in the novel antigen, but in a different order compared to MF_INV_A (Table 2). Two GAd vectors encoding the same 20 neoantigens linked head to tail in the order of Table 2 were prepared: construct CT26-20 (SEQ ID NO: 49) containing only a methionine initiator before the antigen, and construct MF_INV_A-20 (SEQ ID NO: 50) with the mandarin fish constant chain FRAG_A (SEQ ID NO: 7) placed at the N-terminus of the antigen in front of the methionine initiator. In both constructs, the HA peptide sequence (SEQ ID NO: 30) was fused downstream of the antigen in order to monitor expression.
[0186] In 5x10 7 The immune response in BalBC inbred mice was evaluated after a single intramuscular immunization with a dose of 100 virus particles (vp) per group (n=6 per group). Splenocytes were collected two weeks after immunization and tested by IFNγ ELISpot by stimulating the cells in the presence of a pool of 20 synthetic peptides corresponding to the sequences encoding the neoantigens. As previously observed for the small pentatope antigen, the presence of the constant chain FRAG_A of Siniperca chuatsi (SEQ ID NO: 7) strongly enhanced the T cell response after vaccination ( Figure 3 ), regardless of the order and total number of encoded neoantigens.
[0187] Table 2
[0188] Antigenic composition of constructs CT26-20 and MF_INV_A-20: Twenty CT26 neoantigens present in the assembled CT26-20 and MF_INV_A-20 antigens were identified. The neoantigens are present in the antigen in the order shown. The mutated amino acids for each neoantigen are shown in bold and underlined. SEQ ID NOs: 20 to 24 correspond to the five neoantigens present in the pentatope (see Table 1).
[0189]
Claims
1. A polypeptide having T cell response enhancer activity, which consists of: A fragment of a teleost invariant chain (INV) and one or more antigens and / or one or more antigenic fragments thereof, wherein the fragment of the invariant chain consists of 27 amino acids of the membrane proximal domain (MPD) of teleost INV, wherein the MPD is characterized by the amino acid sequence SEQ ID NO:7, wherein in each case, the antigen or antigenic fragment thereof is independently selected from cancer-specific antigens, cancer-specific neoantigens, viral proteins, fungal proteins and bacterial proteins, wherein the cancer-specific antigen is a protein that is specifically expressed in cancer cells or is more abundant in cancer cells than in healthy cells, and wherein the cancer-specific neoantigen is an antigen that is not present in normal cells or germ cells but is present in cancer cells.
2. The polypeptide according to claim 1, wherein: (i) the polypeptide comprises at least five different antigens and / or antigenic fragments thereof; and / or (ii) one or more than one antigen and / or one or more than one antigen fragment thereof is at the C-terminus of the INV fragment according to claim 1.
3. A polynucleotide encoding the polypeptide according to any one of claims 1 to 2. A vector comprising the polynucleotide according to claim 3.
5. A collection of two or more different vectors, wherein each of the different vectors comprises a polynucleotide according to claim 3 encoding a different polypeptide according to any one of claims 1 to 2.
6. The vector according to claim 4 or the collection of vectors according to claim 5, wherein the vector is in each case independently selected from a plasmid; a cosmid; a liposome particle; a viral vector or a virus-like particle.
7. A pharmaceutical composition comprising the polypeptide according to any one of claims 1 to 2, the polynucleotide according to claim 3, or the vector or a collection of vectors according to any one of claims 4 to 6, a pharmaceutically acceptable excipient and optionally one or more than one adjuvant.
8. The pharmaceutical composition according to claim 7, comprising at least one immunomodulator, or at least one polynucleotide encoding an immunomodulator, or a vector or liposome particle comprising a polynucleotide encoding an immunomodulator.
9. A kit of parts, comprising the pharmaceutical composition of claim 7, and at least one immunomodulator, or at least one polynucleotide encoding an immunomodulator, or a vector comprising a polynucleotide encoding an immunomodulator, which are packaged separately.
10. The pharmaceutical composition according to claim 7 or the kit of parts according to claim 9, wherein: (i) The immunomodulator is an MCM and is selected from: (a) agonists of members of the tumor necrosis factor (TNF) receptor superfamily; and / or (b) antagonists of PD-1, CD274, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR, LAG3, TIM-3 or VISTA or antagonists of B7-CD28 superfamily members; and / or (ii) Immunomodulators are T cell growth factors.
